Is Shalby (SHALBY) overvalued or fairly valued?

MarketChacha shows Shalby's valuation in context — a forward P/E of about 17.4, a price-to-book of about 1.7 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Shalby's revenue?

Shalby reported revenue of ₹1,087 Cr for FY2025, with net profit of ₹6 Cr, per official filings.

What is the share price of Shalby (SHALBY)?

Shalby last traded at ₹163.77 (-0.7% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Shalby

SHALBY · NSE · Healthcare · India

₹163.77-0.7%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 9:59 AM

Snapshot

TickerSHALBY

ExchangeNSE

SectorHealthcare

IndustryMedical Care Facilities

CountryIndia

CEOMr. Daniel Hayes

HeadquartersAhmedabad, India

Market cap₹1,757 Cr

P/B1.7

Volume34.1K

Websitewww.shalby.org

Filings tracked0

About Shalby

Shalby Limited operates a chain of multi-specialty hospitals in India and internationally. The company operates through Healthcare Services and Manufacturing segments. It offers rheumatology, knee and hip joint replacement, spine surgery, orthopedic and trauma, arthroscopy, and arthroplasty; cardiothoracic and vascular surgery, coronary angiography, angioplasty and stenting, and cardiology services; root canal treatment, dental implants, crowns bridges, dentures, orthodontic treatment, dental cosmetic, teeth whitening, pediatric dentistry, dental veneers, gum treatment, and laser dentistry; dermatology; emergency and general medicine; cochlear implants and balloon sinuplasty; gastroenterology, obesity surgery, and endoscopy and laparoscopy; intensive and critical care; nephrology, urology, kidney transplant, dialysis, and interventional nephrology; and general surgery comprising varicose, hernia, and piles surgery. The company also provides liver transplant; maxillofacial surgery; neurology, ideal stroke treatment, epilepsy, endovascular/interventional neurosurgery, and trans cranial doppler; obstetrics and gynaecology; surgical oncology, medical oncology, radiation oncology, bone marrow transplant, onco-psychology, onco-dietetics, onco-physiotherapy, and home care; ophthalmology; paediatrics; pathology and microbiology; psychiatry; pulmonology and chest; and interventional and diagnostic radiology. The company was formerly known as Shalby Hospitals Limited and changed its name to Shalby Limited in February 2008. Shalby Limited was founded in 1994 and is based in Ahmedabad, India.

Profile as reported by Yahoo Finance.

Who owns it

Promoters76.6%
Institutions0.1%
Public & other23.4%

6 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

Margin has compressed by about 9.3 points over the period — profitability is trending down.

Net margin trend9.8% → 0.6%

Margin has compressed by about 9.3 points over the period — profitability is trending down.

Growth qualityrev 36% · PAT -47%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

₹125.8252-wk range₹274.70

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 4

Market cap

₹1,757 Cr

Day change

-0.7%

Fwd P/E

17.4

P/B

1.7

Beta

0.56

Revenue (FY2025)

₹1,087 Cr

Net margin

0.6%

Revenue CAGR (3y)

+36.1%

Profit CAGR (3y)

-47.3%

Net profit (FY2025)

₹6 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about SHALBY

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2025	₹1,087 Cr	₹6 Cr	0.6%
FY2024	₹953 Cr	₹83 Cr	8.8%
FY2023	₹827 Cr	₹68 Cr	8.2%
FY2021	₹431 Cr	₹42 Cr	9.8%

Quarterly

Period	Revenue	Net profit	Net margin
2023Q1	₹208 Cr	—	—
2022Q4	₹202 Cr	₹15 Cr	7.5%
2022Q3	₹202 Cr	₹18 Cr	9.1%
2022Q2	—	₹20 Cr	—

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.